Adma Biologics
$9.11
218
+$0.1+1.11% Today
Statistics
Day High
9.6
Day Low
8.99
52W High
25.67
52W Low
7.21
Volume
7,773,935
Avg. Volume
4,822,834
Mkt Cap
2.17B
P/E Ratio
18.21
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
0.195
Actual EPS
N/A
Financials
28.8%Profit Margin
Profitable1.02BRevenue
293.86MNet Income
Analyst Ratings
$0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 0%
Hold 100%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ADMA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
Carlisle Companies
CSL
Mkt Cap13.58B
Grifols SA
GRFS
Mkt Cap7.89B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
Pfizer
PFE
Mkt Cap140.15B
GSK
GSK
Mkt Cap94.51B
Abbvie
ABBV
Mkt Cap385.18B
AMGEN
AMGN
Mkt Cap160.66B
Biogen
BIIB
Mkt Cap22.63B
Johnson & Johnson
JNJ
Mkt Cap455.04B
About
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Show more...
CEO
Mr. Adam S. Grossman
Employees
685
Country
US
ISIN
US0008991046
Listings
0 Comments
Share your thoughts
FAQ
What is Adma Biologics stock price today?▼
The current price of ADMA is $9.11 USD — it has increased by +1.11% in the past 24 hours. Watch Adma Biologics stock price performance more closely on the chart.
What is Adma Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adma Biologics stocks are traded under the ticker ADMA.
Is Adma Biologics stock price growing?▼
ADMA stock has fallen by -5.4% compared to the previous week, the month change is a -41.49% fall, over the last year Adma Biologics has showed a -53.09% decrease.
What is Adma Biologics market cap?▼
Today Adma Biologics has the market capitalization of 2.17B
When is the next Adma Biologics earnings date?▼
Adma Biologics is going to release the next earnings report on May 13, 2026.
What were Adma Biologics earnings last quarter?▼
ADMA earnings for the last quarter are 0.21 USD per share, whereas the estimation was 0.19 USD resulting in a +15.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adma Biologics revenue for the last year?▼
Adma Biologics revenue for the last year amounts to 1.02B USD.
What is Adma Biologics net income for the last year?▼
ADMA net income for the last year is 293.86M USD.
How many employees does Adma Biologics have?▼
As of April 01, 2026, the company has 685 employees.
In which sector is Adma Biologics located?▼
Adma Biologics operates in the Health Care sector.
When did Adma Biologics complete a stock split?▼
Adma Biologics has not had any recent stock splits.
Where is Adma Biologics headquartered?▼
Adma Biologics is headquartered in Ramsey, US.